Attached files
| file | filename |
|---|---|
| 10-Q - Huifeng Bio-Pharmaceutical Technology, Inc. | v194106_10q.htm |
| EX-31.1 - Huifeng Bio-Pharmaceutical Technology, Inc. | v194106_ex31-1.htm |
| EX-31.2 - Huifeng Bio-Pharmaceutical Technology, Inc. | v194106_ex31-2.htm |
| EX-32.1 - Huifeng Bio-Pharmaceutical Technology, Inc. | v194106_ex32-1.htm |
| EX-3.03 - Huifeng Bio-Pharmaceutical Technology, Inc. | v194106_ex3-03.htm |
| EX-10.01 - Huifeng Bio-Pharmaceutical Technology, Inc. | v194106_ex10-01.htm |
| EX-10.02 - Huifeng Bio-Pharmaceutical Technology, Inc. | v194106_ex10-02.htm |
Exhibit
32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report of Huifeng Bio-Pharmaceutical Technology
Inc. on Form 10-Q for the period ended June 30, 2010 as filed with the
Securities and Exchange Commission on the date here of, I, Sanding Tao, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
1. The
Report complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
2. The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
Date:
August 16, 2010
|
/S/
Sanding Tao
|
|
Sanding
Tao
Chief
Financial Officer (Principal Accounting and Financial
Officer)
|